ArticleJournal of clinical medicine2025

Comparative Renal Safety of Tirzepatide and Semaglutide: An FDA Adverse Event Reporting System (FAERS)-Disproportionality Study.

Ayush Gandhi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.